Monitor 3D InSight™ Microtissue viability with Promega technology
The 3D InSight™ Cell Viability Assay Kit provides a rapid and homogeneous method for determining 3D InSight™ Microtissue viability based on quantitation of ATP content, which is an indicator of metabolically active cells
- Achieve reliable quantification of ATP content in 3D InSight™ Microtissues using an assay
with broad sensitivity and compatible lytic capacity
- Rely on a robust, high-throughput-compatible assay format with stable luminescent signal
and simple one step protocol
- Perform multiplex endpoint analyses with other reporter or cell-based assay
This homogeneous biochemical assay quantifies total cellular adenosine-5′-triphosphate (ATP) as an indicator of cellular viability. The assay kit incorporates proprietary luminescent technology from Promega, and is certified for use with InSphero 3D InSight™ microtissues and media. The assay is designed for use with multi-well formats and is ideal for automated high-throughput screening for changes in cellular viability and proliferation during drug efficacy and safety testing. The advanced lytic and sensitive detection capacity of the assay reagent provides an ideal solution for 3D microtissues ensuring robust, reproducible results.
3D InSight™ Cell Viability Assay Kit. This Kit utilizes Promega CellTiter-Glo® 2.0 Assay technology to quantify cellular ATP content in 3D InSight™ Liver, Islet, and Tumor Microtissues. The glow-type luminescence generated in the assay is proportional to the amount of ATP present within the microtissue.
Each 3D InSight™ Cytotoxicity Assay Kit includes the following components, suitable for quantifying ATP in up to 4 x 96-well plates of 3D InSight™ microtissues (including controls):
- Promega CellTiter-Glo® 2.0 Reagent, 10 mL (stable at 4° C for ~4 weeks)
- 10 µM Adenosine-5’-triphosphate (ATP) standard, 750 µL
- Product manual with protocol optimized for 3D InSight™ microtissues
|AK-01-001-01||3D InSight™ Cell Viability Assay Kit|
Note: Available only when purchased with 3D InSight™ Microtissues.
Certified for use with 3D InSight™ Microtissues
3D InSight™ Human Liver Microtissues (coculture model of primary hepatocytes, Kupffer cells and liver endothelial cells) were exposed to Chlorpormazine, a phenothiazine known to cause drug-induced liver injury, over 14 days, with dosings on day 0, 5 and 9. The dose-response curve at the end of treatment showed dramatic decrease in cell viability. (Mean of n=4 with SD).
Total 3D InSight™ Human Islet Microtissue ATP content was assessed after 14 days exposure to varying concentrations of Tunicamycin, an antibiotic that induces endoplasmic reticulum stress and has been shown to cause significant decrease in pancreatic islet viability. Long-term exposure to higher concentrations of Tunicamycin resulted in decreased islet microtissue viability. (Mean of n=6 with SD.)
3D InSight™ HepG2 Tumor Microtissues were exposed to Sunitib, a small-molecule inhibitor of tyrosine kinase receptors, over 10 days, with multiple dosings. Cell viability dose-response curve at end of treatment showed a decline in tumor microtissue viability.